690 related articles for article (PubMed ID: 34614329)
1. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
Witberg G; Barda N; Hoss S; Richter I; Wiessman M; Aviv Y; Grinberg T; Auster O; Dagan N; Balicer RD; Kornowski R
N Engl J Med; 2021 Dec; 385(23):2132-2139. PubMed ID: 34614329
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
Mevorach D; Anis E; Cedar N; Bromberg M; Haas EJ; Nadir E; Olsha-Castell S; Arad D; Hasin T; Levi N; Asleh R; Amir O; Meir K; Cohen D; Dichtiar R; Novick D; Hershkovitz Y; Dagan R; Leitersdorf I; Ben-Ami R; Miskin I; Saliba W; Muhsen K; Levi Y; Green MS; Keinan-Boker L; Alroy-Preis S
N Engl J Med; 2021 Dec; 385(23):2140-2149. PubMed ID: 34614328
[TBL] [Abstract][Full Text] [Related]
3. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Barda N; Dagan N; Ben-Shlomo Y; Kepten E; Waxman J; Ohana R; Hernán MA; Lipsitch M; Kohane I; Netzer D; Reis BY; Balicer RD
N Engl J Med; 2021 Sep; 385(12):1078-1090. PubMed ID: 34432976
[TBL] [Abstract][Full Text] [Related]
4. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
[TBL] [Abstract][Full Text] [Related]
5. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
7. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children.
Dionne A; Sperotto F; Chamberlain S; Baker AL; Powell AJ; Prakash A; Castellanos DA; Saleeb SF; de Ferranti SD; Newburger JW; Friedman KG
JAMA Cardiol; 2021 Dec; 6(12):1446-1450. PubMed ID: 34374740
[TBL] [Abstract][Full Text] [Related]
8. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
10. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
[TBL] [Abstract][Full Text] [Related]
11. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Magen O; Waxman JG; Makov-Assif M; Vered R; Dicker D; Hernán MA; Lipsitch M; Reis BY; Balicer RD; Dagan N
N Engl J Med; 2022 Apr; 386(17):1603-1614. PubMed ID: 35417631
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Barda N; Dagan N; Cohen C; Hernán MA; Lipsitch M; Kohane IS; Reis BY; Balicer RD
Lancet; 2021 Dec; 398(10316):2093-2100. PubMed ID: 34756184
[TBL] [Abstract][Full Text] [Related]
13. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
[TBL] [Abstract][Full Text] [Related]
14. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
15. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
[TBL] [Abstract][Full Text] [Related]
17. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
Sharff KA; Dancoes DM; Longueil JL; Johnson ES; Lewis PF
Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):921-925. PubMed ID: 35404496
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.
Woo W; Kim AY; Yon DK; Lee SW; Hwang J; Jacob L; Koyanagi A; Kim MS; Moon DH; Jung JW; Choi JY; Jung SY; Eun LY; Lee S; Shin JI; Smith L
J Med Virol; 2022 Apr; 94(4):1566-1580. PubMed ID: 34862617
[TBL] [Abstract][Full Text] [Related]
19. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
[TBL] [Abstract][Full Text] [Related]
20. Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age.
Das BB; Kohli U; Ramachandran P; Nguyen HH; Greil G; Hussain T; Tandon A; Kane C; Avula S; Duru C; Hede S; Sharma K; Chowdhury D; Patel S; Mercer C; Chaudhuri NR; Patel B; Ang JY; Asmar B; Sanchez J; Khan D
J Pediatr; 2021 Nov; 238():26-32.e1. PubMed ID: 34339728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
